Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial

Trial Profile

Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 01 Apr 2016 According to ClinicalTrials.gov record number of treatment arms increased from 1 to 3, Secondary endpoint of Adverse Events made Primary and also time frame for this endpoint has been changed from 6 months to 3 months, Time frame for primary endpoint of WOMAC score has been changed from 6 months to 24 months.
    • 05 Dec 2014 Results presented at the 10th Annual World Stem Cell Summit (WSCS) and RegMed Capital Conference (RMCC), according to Cellular Biomedicine Group media release.
    • 05 Dec 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top